Concurrent Weekly Cisplatin and Simultaneous Integrated Boost Intensity-Modulated Radiotherapy of Locally Advanced Squamous Cell Carcinoma of Head and Neck

Published: 18 November 2020| Version 2 | DOI: 10.17632/gynvvkb4ps.2
Pavol Dubinsky,
Branislav Jeremic,
Michaela Svajdova,
Gabriela Barilikova,
Pavol Matula,
Daniela Nadzonova,
Vladimir Vojtek


This is the dataset of 40 patients with locally advanced squamous cell carcinoma of the head and neck in stage III and IVA (TNM 7th Ed.) prospectively treated with simultaneous integrated boost intensity-modulated radiotherapy with concurrent weekly cisplatin at the Department of Radiation Oncology of the East Slovakia Institute of Oncology. Long-term treatment outcomes, acute and late toxicity were evaluated.


Steps to reproduce

The dataset was statistically analysed by the statistical program IBM SPSS. The endpoints of analysis were locoregional control rate, distant control rate, progression-free survival, overall survival and toxicity. All survival data were calculated from the date of the first fraction of radiotherapy. Cumulative survival data were calculated using the Kaplan – Meier method. Univariate and multivariate analyses using the Cox regression model were performed for the total cohort patients to determine the prognostic significance of the following factors: HPV status, cisplatin cumulative dose, overall treatment time prolongation, stage and tumor site. Univariate analysis using Cox regression model was subsequently performed for the subgroup of HPV negative SCCHN patients.


Oncology, Radiation, Cancer, Chemotherapy, Toxicity